论文部分内容阅读
目的观察大黄虫丸在治疗慢乙肝中抗肝纤维化的临床疗效。方法对45例常规护肝治疗的慢乙肝患者加用大黄虫丸,同期45例常规护肝治疗的慢乙肝患者作对照。结果两组护肝疗效和转归相同,无显著性差异(P>0.05);另观察到血清肝纤维化标志物(HA,LN,PⅢP,Ⅳ-C,CG)的改善、大黄虫丸组均显优于对照组(P<0.05)。结论大黄虫丸对慢乙肝抗肝纤维化有确切疗效;其抗肝纤维化的疗效与大黄蜃虫丸活血破瘀、软坚散结、清热解毒及显著抑制基质金属蛋白酶抑制剂(TIMP)直接相关,与常规护肝药物无直接关系。
Objective To observe the curative effect of Dahuangchong Pill in the treatment of chronic hepatitis B against liver fibrosis. Methods 45 patients with chronic hepatitis B treated with routine hepatoprotective therapy were treated with Dahuangchong Pills. In the same period, 45 patients with chronic hepatitis B treated with routine hepatoprotective therapy were used as controls. Results There was no significant difference in the efficacy and outcome of liver protection between the two groups (P>0.05). In addition, serum hepatic fibrosis markers (HA, LN, PIIIP, IV-C, CG) were improved, and Dahuangchong Pills group was observed. Both were significantly better than the control group (P<0.05). Conclusion Dahuangchong Pill has a definite effect on anti-hepatic fibrosis of chronic hepatitis B; its anti-hepatic fibrosis effect is directly related to rhubarb aphid pill in promoting blood circulation and turbinate stasis, soft-endossification, detoxification, and significant inhibition of matrix metalloproteinase inhibitor (TIMP). There is no direct relationship with conventional liver protection drugs.